Commercial

J&J sets the tone for Q1 earnings with strong oncology growth

Pharmaceutical Technology

Off the back of J J's positive Q1, CEO Joaquin Duato forecasts strong growth acceleration for 2026, driven partially by psoriasis med Icotyde

Commercial Oncology Read full story

pharminent April 15, 2026

Pharmaceutical Technology

Off the back of J J’s positive Q1, CEO Joaquin Duato forecasts strong growth acceleration for 2026, driven partially by psoriasis med Icotyde

Commercial Oncology Read full story